Unprecedented drug for treatment of insomnia will be marketed in Brazil, in 2019
Published in: February 12, 2019
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, April 2019 – Eurofarma has announced that it has received the approval from the National Sanitary Surveillance Agency (Anvisa) to market Prysma® (eszopiclone), an innovative and new molecule in the Brazilian market for the insomnia treatment. The novelty arrives in the country in 2019.
Prysma® has been shown to be effective and safe in adult patients who have difficulty initiating or maintaining sleep, providing up to 8 hours of rest.
In studies conducted in patients with various types of insomnia – including the chronic one – from adults, women to the elderly who also had insomnia associated with psychological disorders such as anxiety and depression, the drug demonstrated efficacy in improving sleep parameters and performance in daily activities, associated with better quality of sleep and greater sense of well-being. Moreover, they have not experienced clinical issues related to dependence, rebound effect or development of tolerance with long-term use.
In Brazil, a phase III clinical study was performed, and Prysma® (eszopiclone) presented greater total time and better sleep efficiency when compared to another insomnia medication with a similar safety profile.
According to the Brazilian Sleep Association, it is estimated that more than 70 million Brazilians have repetitive difficulties in starting or maintaining sleep, which can cause moodiness, irritability, low productivity, memory problems and tiredness.
"We will launch Prysma®, which inaugurates the 1st category of Anvisa as a diverse innovator and is the only one of the 3rd generation of sleep inducers in Brazil, offering physicians and their patients an option for up to 8 hours of sleep that do not causes dependence and with fewer side effects than benzodiazepines," explains Roberta Junqueira Nóbrega, Commercial Director of the Prescription Medical Unit of Eurofarma.
About the Eurofarma Group
The Eurofarma Group is a healthcare company focused on offering products and services to improve people's lives with quality, innovation and fair price in the areas of Medical Prescription, Prescription Exempt, Generic, Hospital, Oncology and Veterinary. In Brazil alone, the company offers 287 products in 622 presentations, serves 30 medical specialties and covers 101 therapeutic classes, which represent 89% of pharmaceutical retail sales.
Founded in 1972 and as the first multinational pharmaceutical company with 100% Brazilian capital, it has its own operations in 20 countries, maintaining an important industrial site in Brazil and plants in 6 other Latin American countries. In 2018, the group generated sales of R$ 4.3 billion and employs more than 6.7 thousand employees.
For further information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
For press information:
Eurofarma Laboratories
Stephanie Van Sebroeck - +55 11 5090-8600 r.8369 - stephanie@gaspar.com.br
Guilherme Gaspar – Phone +55 11 3065-3045 – guilherme@gaspar.com.br
Prysma® has been shown to be effective and safe in adult patients who have difficulty initiating or maintaining sleep, providing up to 8 hours of rest.
In studies conducted in patients with various types of insomnia – including the chronic one – from adults, women to the elderly who also had insomnia associated with psychological disorders such as anxiety and depression, the drug demonstrated efficacy in improving sleep parameters and performance in daily activities, associated with better quality of sleep and greater sense of well-being. Moreover, they have not experienced clinical issues related to dependence, rebound effect or development of tolerance with long-term use.
In Brazil, a phase III clinical study was performed, and Prysma® (eszopiclone) presented greater total time and better sleep efficiency when compared to another insomnia medication with a similar safety profile.
According to the Brazilian Sleep Association, it is estimated that more than 70 million Brazilians have repetitive difficulties in starting or maintaining sleep, which can cause moodiness, irritability, low productivity, memory problems and tiredness.
"We will launch Prysma®, which inaugurates the 1st category of Anvisa as a diverse innovator and is the only one of the 3rd generation of sleep inducers in Brazil, offering physicians and their patients an option for up to 8 hours of sleep that do not causes dependence and with fewer side effects than benzodiazepines," explains Roberta Junqueira Nóbrega, Commercial Director of the Prescription Medical Unit of Eurofarma.
About the Eurofarma Group
The Eurofarma Group is a healthcare company focused on offering products and services to improve people's lives with quality, innovation and fair price in the areas of Medical Prescription, Prescription Exempt, Generic, Hospital, Oncology and Veterinary. In Brazil alone, the company offers 287 products in 622 presentations, serves 30 medical specialties and covers 101 therapeutic classes, which represent 89% of pharmaceutical retail sales.
Founded in 1972 and as the first multinational pharmaceutical company with 100% Brazilian capital, it has its own operations in 20 countries, maintaining an important industrial site in Brazil and plants in 6 other Latin American countries. In 2018, the group generated sales of R$ 4.3 billion and employs more than 6.7 thousand employees.
For further information, visit www.eurofarma.com.br
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram: @eurofarma_br
For press information:
Eurofarma Laboratories
Stephanie Van Sebroeck - +55 11 5090-8600 r.8369 - stephanie@gaspar.com.br
Guilherme Gaspar – Phone +55 11 3065-3045 – guilherme@gaspar.com.br